Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH 2017
Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL
ASH 2017
,
ASH Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
ZUMA-1 is a pivotal, multicenter trial of axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients with refractory, aggressive non-Hodgkin lymphoma (NHL). The objective response rate (ORR) was 82% with a 54% rate of complete response (CR), and 44% of responses were ongoing at the time of the primary analysis. Grade ≥3 cytokine release syndrome (CRS) and neurologic events (NEs) occurred in 13% and 28% of patients, respectively.
Read Article
Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
ASH 2017
,
ASH Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Brentuximab vedotin (BV), an antibody drug conjugate, selectively delivers the antitubulin agent, monomethyl auristatin E, to CD30+ cells. In a multicenter phase 2 trial in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL), BV showed an overall response rate (ORR) of 75%, a complete response (CR) rate of 34%, and a median duration of response (DOR) of 6.7 months.
Read Article
Precision Medicine and Immunotherapy Highlighted at ASH 2017
By
Wayne Kuznar
ASH 2017
,
ASH Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—More than 25,000 attendees converged on Atlanta during the middle of a rare winter snowstorm to attend ASH 2017, which featured nearly 5000 scientific abstract presentations ranging from cutting-edge advances in gene therapy and personalized medicine to practice-changing discoveries in immunotherapies.
Read Article
Nivolumab plus Azacitidine Shows Encouraging Activity in R/R AML or as Frontline Therapy in Elderly Patients with AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
,
ASH Highlights
Conference Correspondent
Combination treatment with nivolumab plus azacitidine produced encouraging response rates in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with poor-risk features, and in elderly patients as frontline therapy.
Read Article
Dual FLT3 and CDK4/6 Inhibition Shows Modest Activity in Relapsed/Refractory AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
,
ASH Highlights
Conference Correspondent
A phase 1 dose-escalation study of FLX925, a dual FLT3 and CDK4/6 inhibitor, showed modest antileukemic activity in adult patients with relapsed or refractory acute myeloid leukemia (AML).
Read Article
Continuing Enasidenib Treatment Improves Survival and Responses for Mutant-IDH2 R/R AML Patients with Stable Disease
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
,
ASH Highlights
Conference Correspondent
An analysis of response and survival outcomes from the phase 1/2 AG221-C-001 study showed that continued treatment with enasidenib resulted in improved survival and response times in patients with mutant-
IDH2
relapsed or refractory (R/R) acute myeloid leukemia (AML).
Read Article
Lirilumab plus Azacitidine in Heavily Pretreated, Relapsed AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
,
ASH Highlights
Conference Correspondent
The results of the current phase 1b/2 study showed that the combination of azacitidine plus lirilumab was well-tolerated in heavily pretreated patients with relapsed acute myeloid leukemia (AML) and poor-risk disease features.
Read Article
Venetoclax plus Decitabine or Azacitidine in Treatment-Naïve, Elderly Patients with AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
,
ASH Highlights
Conference Correspondent
An updated safety and efficacy analysis of a phase 1b study demonstrated a promising benefit–risk profile with the combination of the BCL-2 inhibitor venetoclax with either decitabine or azacitidine in elderly, treatment-naïve patients with acute myeloid leukemia (AML) who are not candidates for intensive standard induction therapy.
Read Article
Addition of Midostaurin to Standard Chemotherapy in RATIFY Decreased CIR in Patients with FLT3-Mutated, Newly Diagnosed AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
,
ASH Highlights
Conference Correspondent
The results of a post-hoc analysis of the RATIFY trial suggest that midostaurin decreases the cumulative incidence of relapse (CIR) in patients with
FLT3
mutation–positive, newly diagnosed acute myeloid leukemia (AML), with no negative impact on survival.
Read Article
Ivosidenib Monotherapy Results in Deep mIDH1 Clearance in Patients with mIDH1 AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
,
ASH Highlights
Conference Correspondent
This analysis showed that ivosidenib-treated patients with
IDH1
-mutated (m
IDH1
), relapsed/refractory, and untreated acute myeloid leukemia (AML) whose best response is a complete remission (CR) or CR with partial hematologic recovery achieve m
IDH1
clearance ≤0.04%.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma